Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focusing on the development and marketing of innovative pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases. This area of high unmet medical need includes many orphan and niche indications with no current therapy.
Santhera strategically focuses on Raxone® (INN: idebenone). Raxone has received European Marketing Authorization for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).
In addition, Raxone is currently being developed in Duchenne Muscular Dystrophy (submissions for marketing application in the USA and Europe pending) and primary progressive Multiple Sclerosis (ppMS) (in Phase II).
The second compound in the clinical pipeline is omigapil for the treatment of Congenital Muscular Dystrophies.
Fipamezole is available for partnering after successfully completed Phase II development for treatment of levodopa-induced Dyskinesia in Parkinson's Disease.